Nancy Whiting

Executive VP, Late Stage Development at Seattle Genetics

Nancy has broad experience in drug development and medical affairs. Since joining Seattle Genetics, she has made many contributions to the company, including driving the development strategy for ADCETRIS and tucatinib, and providing important scientific contributions to all our programs.

Org chart

Manager

Clay B. Siegall

Chairman, President & CEO

Peers

Tuomo Pätsi

Executive Vice President, Commercial International

Todd E. Simpson

Chief Financial Officer

Vaughn B. Himes

Chief Technical Officer

Teams

CEO and Executive Team

8 members

Leadership Team

9 members

Timeline

Executive VP, Late Stage Development
Current role

View in org chart